VALEANT Pharmaceuticals International Inc reduce its 2016 income forecast by about 12 p.c and mentioned a delay in submitting its annual report may pose a default danger.
The Canadian drugmaker, the goal of U.S. investigations into its enterprise and accounting practices, reiterated that it will delay submitting its annual report to U.S. regulators however for the primary time raised the spectre of a default because of this.
Valeant, whose U.S.-listed shares had been down 18.3 p.c in premarket buying and selling, mentioned failure to file the report by Tuesday’s deadline would imply it will be in breach of a covenant and that holders of not less than 25 p.c of any collection of notes could ship a discover of default.
As of Sept. 30, Valeant had about $30 billion of long-term debt. However, Chief Executive Michael Pearson expressed optimism in regard to the firm’s funds.
“We are comfortable with our current liquidity position and cash flow generation for the rest of the year, and remain well positioned to meet our obligations,” he mentioned in a press release.
The firm mentioned final month it will delay submitting its annual report whereas a board committee appeared in its accounting practices. The firm additionally mentioned it will restate 2014, and 2015 monetary statements.
Valeant’s troubles started late final 12 months when questions had been raised about its drug pricing technique and allegations emerged that it was utilizing drug distributor Philidor RX Services to inflate income in its dermatology enterprise.
